First Personal Financial Services trimmed its stake in McKesson Co. (NYSE:MCK) by 10.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,322 shares of the company’s stock after selling 284 shares during the period. First Personal Financial Services’ holdings in McKesson were worth $321,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Venturi Wealth Management LLC bought a new position in McKesson in the third quarter worth about $27,000. Usca Ria LLC purchased a new stake in McKesson in the third quarter worth about $27,000. Prime Capital Investment Advisors LLC purchased a new stake in McKesson in the third quarter worth about $27,000. Vista Private Wealth Partners. LLC bought a new stake in McKesson during the 3rd quarter valued at approximately $35,000. Finally, CSat Investment Advisory L.P. boosted its position in McKesson by 165.8% during the 2nd quarter. CSat Investment Advisory L.P. now owns 295 shares of the company’s stock valued at $40,000 after acquiring an additional 184 shares in the last quarter. 87.29% of the stock is currently owned by hedge funds and other institutional investors.
In other McKesson news, CEO Brian S. Tyler sold 4,062 shares of McKesson stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $153.68, for a total transaction of $624,248.16. Following the completion of the transaction, the chief executive officer now owns 16,254 shares in the company, valued at $2,497,914.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.88% of the stock is currently owned by insiders.
MCK has been the subject of several research reports. Mizuho increased their target price on McKesson from $137.00 to $140.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 15th. TheStreet lowered McKesson from a “b” rating to a “c-” rating in a research report on Wednesday, October 30th. Morgan Stanley upgraded McKesson from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $135.00 to $162.00 in a research report on Friday, January 10th. UBS Group downgraded McKesson to a “sell” rating and set a $147.00 price objective for the company. in a report on Thursday, January 9th. Finally, Barclays reiterated a “hold” rating and issued a $170.00 price objective on shares of McKesson in a report on Sunday, January 19th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $153.70.
Shares of NYSE MCK opened at $152.62 on Friday. McKesson Co. has a fifty-two week low of $110.52 and a fifty-two week high of $156.97. The company has a 50 day simple moving average of $143.21 and a two-hundred day simple moving average of $142.42. The company has a market capitalization of $27.50 billion, a price-to-earnings ratio of -43.36, a P/E/G ratio of 1.50 and a beta of 1.12. The company has a debt-to-equity ratio of 1.36, a quick ratio of 0.57 and a current ratio of 1.01.
McKesson (NYSE:MCK) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $3.60 EPS for the quarter, hitting analysts’ consensus estimates of $3.60. The firm had revenue of $57.62 billion for the quarter, compared to analysts’ expectations of $55.06 billion. McKesson had a positive return on equity of 32.77% and a negative net margin of 0.29%. The business’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.60 EPS. On average, analysts forecast that McKesson Co. will post 14.68 earnings per share for the current fiscal year.
McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.
Recommended Story: Why are percentage gainers important?
Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Co. (NYSE:MCK).
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.